Skip to main content
OpenTrials
Completed

NCT Number: NCT05099198

Replication of the GRADE Diabetes Trial in Healthcare Claims Data

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Brigham and Women's Hospital

Boston, Massachusetts, 02120, United States

About this study

This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as is possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age greater or equal than 30: days [0,0]
  • Diagnosis of Type 2 Diabetes: days [- All Data, 0]
  • 2+ recorded HbA1c levels: days [-365,0]
  • Metformin use: days [-30, 0]

Exclusion criteria

  • Type 1 or Secondary DM: days [-All Data, 0]
  • Previous organ transplant: days [-All Data, 0]
  • HIV/AIDS: days [-All Data, 0]
  • History of bariatric surgery: days [-All Data, 0]
  • Congestive heart failure: days [-All Data, 0]
  • NYHA >=3: days [-All Data, 0]
  • Pancreatitis: days [-All Data, 0]
  • Medullary thyroid cancer/MEN-2: days [-All Data, 0]
  • History of MI: days [-365, 0]
  • Stroke: days [-365, 0]
  • Coronary Revascularization: days [-365, 0]
  • PTCA/Stenting/CABG: days [-365, 0]
  • Trans myocardial revascularization: days [-365, 0]
  • Carotid bypass: days [-365, 0]
  • Cerebrovascular revascularization: days [-365, 0]
  • PVD: days [-365, 0]
  • CCI >=10: days [-365, 0]
  • History of cancer, other than non-melanoma skin cancer: days [-1,825, 0]
  • Treatment of metformin more than 10 years: days [-3,650, 0]
  • Treatment with any diabetes drug other than metformin; PCOS; symptomatic hyperglycemia; pregnancy; gestational diabetes: days [-180, 0]
  • History of hemolytic anemia; history of severe liver disease; current alcoholism; chronic transfusion requirement; ESRD: days [-180, 0]
  • Oral, IV, or IM cortisone, hydrocortisone, prednisone, methylprednisone, or dexamethasone: days [-90, 0]
  • Treatment with atypical antipsychotics, language barriers, nursing home, or missing age or gender: days {-180, 0]
  • Hospitalization with length of stay >3 days: days [-30, 0]

Treatment and study plan

Sitagliptin

Drug

Sitagliptin dispensing claim is used as the reference

Glimepiride

Drug

Glimepiride dispensing claim is used as the reference

Primary outcomes

  1. Time until failure to maintain metabolic control

    Time frame: Through censoring or study completion, up to 765 days after cohort entry

    Lab based algorithm: time until failure to maintain metabolic control (HbA1c level >= 7.0% or 53 mmol/mol)

Secondary outcomes

  1. Time until a severe hypoglycemic episode

    Time frame: Through censoring or study completion, up to 765 day after cohort entry

    Claims based algorithm: time until a severe hypoglycemic episode

  2. HbA1C change from baseline

    Time frame: Through censoring or study completion, up to 765 days after cohort entry

    Lab based algorithm: HbA1C change from baseline

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Registry information

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Oct 29, 2021
Registry last updated
Jul 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.